Coherus joins biosimilar Humira melee
This article was originally published in Scrip
Executive Summary
Coherus BioSciences' CHS-1420, its proposed biosimilar of adalimumab (Humira), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira in healthy subjects.